Ed Robinson, Ph.D.

Edward D. Robinson, J.D., Ph.D.

Dr. Robinson is a registered patent attorney with the U.S. Patent and Trademark Office
(USPTO) and is admitted to practice law in the state of California. He specializes in advising
corporations and universities in obtaining patent protection for their biotech, chemical,
pharmaceutical, and medical device inventions. Having over ten years of experience in
preparing and prosecuting U.S. and foreign patent applications, he regularly advises clients
on their patent portfolio and patent strategy. In addition, Dr. Robinson also counsels on
various business and licensing transactions by conducting intellectual property due diligence
investigations, as well as in authoring opinion letters regarding patent invalidity and non-
infringement.

Dr. Robinson received his Bachelor of Science degree in Chemistry from Rowan University,
and his Ph.D. in synthetic organic chemistry from the University of Delaware. After doing
post-doctoral studies in synthetic organic and medicinal chemistry at the University of South
Carolina and The Upjohn Company, Dr. Robinson worked as a medicinal chemist at several
San Diego biotech companies before going into law. Dr. Robinson received his J.D. from the
University of San Diego School Of Law in May of 2002. While in law school, Dr. Robinson
worked as a patent agent at Isis Pharmaceuticals and Heller Ehrman LLP. After graduating
from law school, Dr. Robinson worked as Corporate Counsel at Pfizer Inc., as an Associate
at Townsend, Townsend and Crew LLP, and as Of Counsel at DLA Piper LLP before joining
Tech Law LLP.

In addition to his admission to the USPTO and California bars, Dr. Robinson is also a long-
standing member of the American Chemical Society, American Bar Association, American
Intellectual Property Law Association, San Diego Intellectual Property Law Association, and
the Licensing Executives Society.

Dr. Robinson can be reached by e-mail at ed@techlawllp.com, or by telephone at 619.213.7483.



Test Your TTAB Judge-Ability on these Two Genericness Appeals: The Board decided two genericness cases in earl... http://t.co/4kzvLL4Hoa